Background: Prostaglandins play a major role in inflammation and pain. They are
Introduction
The analgesic and anti-inflammatory actions of nonsteroidal anti-inflammatory drugs (NSAIDs) have traditionally been attributed to their inhibition of peripheral prostaglandins (PG) 1, 2 . PGs are synthesised from arachidonic acids by two cyclooxygenase isoforms (COX1 and COX2) and play a major role in sensitising nociceptors at the site of tissue injury 3 . COX-1 is constitutively expressed in many cell types whereas COX-2 is induced at the site of inflammation 4 . Most conventional NSAIDs non-preferentially inhibit both COX isozymes. Their analgesic effects are thought to be mostly due to their inhibiting the COX-2 isoform, and their adverse effects from inhibiting COX-1. Thus, the development of selective COX-2 inhibitors has contributed significantly to therapeutic progress as these molecules have similar anti-inflammatory and analgesic properties but are better tolerated clinically 5, 6 . However, recent data on acute cardiovascular toxicity has lead to new recommendations for their use [7] [8] [9] . Thus, there is active research into the mechanisms of NSAIDs action with the aim of improving their clinical use.
A growing body of experimental evidence suggests that, in addition to their well established peripheral effects, NSAIDs may also exert their analgesic action directly within the central nervous system (CNS) 2, 10 . Both COX isoforms are constitutively expressed in rat brain and spinal cord 11, 12 . COX-2 is the predominant isoform in the spinal dorsal horn and could play a role, not only in pathological inflammatory pain, but also in normal physiological pain (i.e. without inflammation). There are few experimental data confirming the role of constitutive COX-2 in normal pain processing in animal models 2, 13 . RIII reflex recordings have been used in numerous pharmacological studies related to analgesia in humans [19] [20] . In particular, it was used to reveal the central action of conventional NSAIDs (i.e. mixed COX1-COX2 inhibitors) on nociceptive processes [21] [22] [23] . In the present study, we tested the effects of parecoxib on the RIII reflex stimulus-response curves. We also analysed the effects of parecoxib on the progressive increase of the reflex response and resulting sensation induced by repeated series of stimuli at relatively a high frequency (i.e. 1 Hz) of fixed intensity. This "wind-up" phenomenon, is due to the summation of nociceptive input over time (i.e. 
Methods
The experiments were approved by a local Ethics Committee and carried out on 12 paid healthy volunteers. The volunteers were carefully briefed about the experimental procedures and gave informed written consent for their participation in the study.
Electrophysiological recording of the RIII reflex
During the recordings, the subjects sat comfortably reclined to ensure a state complete muscular relaxation. (Fig 1) The nociceptive flexion reflex (RIII) was evoked and recorded with a computerised system (Notocord Systems, Croissy, France), using previously described techniques [25] [26] . Briefly, the sural nerve was electrically stimulated at a rate of 0.1 Hz using a pair of surface electrodes placed 2 cm apart on the 
Experimental procedure
This pharmacological study was organised as a double-blind, cross-over trial. We randomly assigned a placebo (saline) or 1 mg/kg of parecoxib (Laboratoire Pfizer, Paris, France) in a 10 ml volume of 10 ml, which was injected intravenously over a period of 10 min, with a maximum parecoxib dose of 80 mg. This dose was chosen because it was in the range used in clinical trials [27] [28] . The maximum dose corresponds to the daily maximum dose authorised for clinical use in France. The experiments were carried out in the volunteers twice, with each experiment separated by an interval of seven days.
Six stimulation sequences were used on each experimental day: two before injection 
Effects of Parecoxib on the Recruitment Curve of the Nociceptive Flexion

Reflex
The area under the RIII reflex recruitment curves (AUC) were similar before the injection of parecoxib or placebo (Fig 2) . After administration of parecoxib, the AUC progressively and significantly decreased between 20 to 60 minutes, returning to baseline values at 80 minutes (Fig 2A) . By contrast, we observed no significant change of AUC after administration of the placebo. The effects due to parecoxib were significantly different from those due to placebo (p< 0.05) at 40 and 60 minutes. The effects on the recruitment curve were not influenced by the sequence (parecoxibplacebo or placebo-parecoxib) or the period (first or second session). Fig 3, the decrease in AUC was due to the slope of the recruitment curve decreasing, with no significant change in the RIII reflex threshold at any time after the injection. Thus, the mean RIII threshold, which was not significantly different at baseline between the parecoxib (7.8 ± 1 mA) and placebo (7.0 ± 0.7 mA) groups, was not significantly altered 60 minutes after treatment (7.5 ± 1.0 mA after parecoxib and 6.2 ± 0.6 mA after placebo). By contrast, the mean tolerance threshold (i.e. the maximum stimulus intensity on the recruitment curve), which was not significantly different at baseline between the parecoxib (14.3±2.7 mA) and placebo (15.0± 3.6 mA) groups, was significantly higher (p < 0.05) 40 and 60 minutes after administration of parecoxib (i.e. 17.2 ± 2.4 mA and 17.3 ± 2.0 mA) than after the placebo (14.1 ± 1.1 mA and 14.0 ± 1.3 mA).
As illustrated in
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Effects of parecoxib on the wind up phenomenon As previously described [25] [26] , applying a series of 15 stimuli at 1.2 times the reflex threshold and at a frequency of 1 Hz, progressively increased the reflex responses (up to 250% of the first response). This wind-up of the RIII reflex, due to the temporal summation of nociceptive stimuli, was similar during the two control periods and did not significantly change after administration of the placebo or parecoxib (Fig 4) . Consistent with these electrophysiological results, the progressive increase in pain sensation during the application of high frequency stimulation was similar in the two treatment groups at baseline (VAS score increased from 21.6±8 to 52 ± 12 in the parecoxib group and from 23.6±11 mm to 49± 15 in the placebo group) and was not significantly different after administration of parecoxib or placebo. . In accordance with electrophysiological and behavioral data in animals 13 , our results indicate that constitutive COX-2 and probably prostaglandins are involved in normal nociceptive processing in humans. However, since in our study parecoxib was injected intravenously, we cannot exclude that it also acts supraspinally and the modulation of the RIII reflex involved descending controls. . The fact that COX-2 inhibitors reduced secondary hyperalgesia also suggest an action on central sensitization 14, 15 . In the present study, we investigated the effects of parecoxib on the progressive increase (i.e. "wind-up") of the RIII reflex induced by the temporal summation of the nociceptive inputs, which may be related to central sensitisation 24, 36 . 
